Pharm prime vendor fleet
Ended Awarded Last action
- Contract number
- SPE2DU26F0H39
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,381
Award facts
- Contract value 100% obligated
- $1,381.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order valued at $1,381.12 from the Defense Logistics Agency on December 7, 2025. This firm fixed-price delivery order falls under the company's single-award Indefinite Delivery Contract (IDC) with a $499.999 billion ceiling value established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025. The broader PPV-G GEN V acquisition strategy, valued at $30.3 billion, designates DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to supply a comprehensive range of pharmaceutical products to Department of Defense military healthcare facilities worldwide. The contract was awarded without set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement.
This delivery order authorizes the supply of firm fixed-price pharmaceutical products and medical consumables to support recurring medical supply needs across the DoD healthcare system. DMS Pharmaceutical Group's product portfolio encompasses branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables, including oncology treatments, immunosuppressants, emergency medications, and routine pharmaceuticals. The parent IDC, which extends through December 31, 2036, and includes a 30-month base period with three 30-month option periods, positions DMS Pharmaceutical Group as a critical supplier within the federal pharmaceutical supply chain supporting military healthcare operations globally. No subcontractor relationships were identified in the award documentation.
Quick answers
Who was awarded contract SPE2DU26F0H39?
SPE2DU26F0H39 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 7, 2025.
How much is contract SPE2DU26F0H39 worth?
The government has obligated $1,381 on SPE2DU26F0H39.
Is contract SPE2DU26F0H39 an order under another contract?
Yes. SPE2DU26F0H39 is a delivery order under SPE2DU25D9803, an indefinite delivery contract.
Was contract SPE2DU26F0H39 competed?
The extent of competition for SPE2DU26F0H39 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award